Aytu Bioscience acquires rights to Natesto drug

Aytu Bioscience acquires rights to Natesto drug

ENGLEWOOD -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology, today announced the exclusive licensing... Read More

Monday April 25, 2016 0 comments Tags: Aytu BioScience, Englewood, Natesto, Acerus Pharma, Josh Disbrow, Tom Rossi